Tag: CIRSE 2020

immuno-oncology

Combination of immuno-oncology and liver-directed therapy: Where do we stand?

Ushering in “the era of IO”, Brad Wood calls for interventional oncologists to learn the language of immuno-oncology—“the other IO”—in order to improve care...
thrombectomy

New devices for endovascular thrombectomy discussed at CIRSE

In a session of the 2020 Cardiovascular and Radiological Society of Europe (CIRSE) meeting (12–15 September, virtual) focused on the hottest news in the...
Biotronik

CIRSE 2020: New clinical data support use of 4F devices for...

Outcomes of the BIO4AMB trial demonstrated that ambulatory treatment with 4­-French (4F) devices is a valid and safe option for endovascular treatment of lower...
fertility

Fertility after uterine artery embolization: Still an unsolved issue, CIRSE delegates...

Fertility in patients who have had uterine artery embolization (UAE) is still a “hot topic,” Jean-Pierre Pelage (University Hospital and Medical Center, Caen, France)...
IRE

CROSSFIRE trial: IRE induces a more immune-permissive environment in pancreatic cancer...

Irreversible electroporation (IRE) significantly induces a window of reduced immune suppression two weeks post treatment, allowing the activation of effector T cells that seem...
rivaroxaban

Patients with multiple revascularisations are at higher risk of acute limb...

Symptomatic peripheral arterial disease (PAD) patients undergoing recurrent lower extremity revascularisation have higher rates of ischaemic events, particularly acute limb ischaemia, than those patients...
reimbursement

Calls in Germany for reimbursement as analysis shows drug-eluting technology is...

Stefan Müller-Hülsbeck (Ev Luth Diakonissenanstalt zu Flensburg, Flensburg, Germany) presented attendees of the online meeting of the Cardiovascular and Interventional Radiological Society of Europe...
Luminor

“No signal of increased risk of long-term mortality” with paclitaxel-coated Luminor...

An ad hoc, two-year analysis of the EffPac study found no signal of increased risk of long-term mortality, nor any adverse events, within two...
SAVER

Win for paclitaxel as SAVER registry “reinforces the safety profile” of...

“The SAVER registry reinforces the safety and effectiveness profile for the Stellarex drug-coated balloon (DCB; Philips) in a real-world patient population,” Konstantinos Stavroulakis (St...
covered

24-month AVeNEW study results: Covered stent angioplasty “statistically superior” to angioplasty...

Against the backdrop of increasing end-stage renal disease (ESRD) prevalence in the USA, Bart Dolmatch (Portola Valley, USA) presented the 24-month results of the...
predict

New prediction model for target lesion revascularisation grants “new level of...

“Please feel free to utilise this in your practice,” Michael Dake (University of Arizona Health Sciences, Tucson, USA) urged on the first day of...

The largest European cohort on the treatment of liver cancer with...

The largest European-wide observational study on the treatment of primary and metastatic liver tumours with SIR-Spheres microspheres (Sirtex) will present its data on safety...
CIRSE

The first virtual CIRSE: What you need to know

Ahead of the first ever virtual meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), Thomas Kröncke, chairperson of the CIRSE 2020...
meeting

CIRSE 2020 to take place online

The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Scientific Meeting will be taking place online 12–15 September. Read the full press release...